Curcumin Up Regulates T Helper 1 Cells in Patients with Colon Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2017 May 5

PMID 28469791

Citations 39

Authors

Bin Xu

Lin Yu

Li-Zhong Zhao

Affiliations

Soon will be listed here.

Abstract

The therapy for the advanced colon cancer (Cca) is unsatisfactory currently. To regulate the immune effector cell function has shown a positive effect on the treatment of advanced cancers. This study tests a hypothesis that administration with curcumin converts the Cca patient-derived regulatory T cells (Treg) to T helper (Th) 1 cells. In this study, a group of patients with advanced Cca was recruited into this study. The patients were treated with curcumin. The peripheral Tregs and Th1 cells were assessed by flow cytometry. The results showed that, after the curcumin therapy, the forkhead box protein (Foxp) 3 positive Treg frequency was markedly reduced, the frequency of Th1 cells was significantly increased in Cca patients. Treating with curcumin repressed the Foxp3 gene transcription in Tregs; the Tregs were then converted into Th1 cells. The results also revealed that Foxp3 bound T-bet to prevent IFN-γ expression in CD4 T cells, which was abolished by treating with curcumin. In conclusion, the administration of curcumin can convert Tregs to Th1 cells via repressing Foxp3 expression and enhancing IFN-γ production.

Citing Articles

A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer.

Shadnoush M, Momenan M, Seidel V, Tierling S, Fatemi N, Nazemalhosseini-Mojarad E Pharmacol Rep. 2024; 77(1):103-123.

PMID: 39304638 DOI: 10.1007/s43440-024-00652-y.

Modulatory Role of Phytochemicals/Natural Products in Cancer Immunotherapy.

Vijayan Y, Sandhu J, Harikumar K Curr Med Chem. 2024; 31(32):5165-5177.

PMID: 38549529 DOI: 10.2174/0109298673274796240116105555.

The Combination of Bioavailable Concentrations of Curcumin and Resveratrol Shapes Immune Responses While Retaining the Ability to Reduce Cancer Cell Survival.

Focaccetti C, Palumbo C, Benvenuto M, Carrano R, Melaiu O, Nardozi D Int J Mol Sci. 2024; 25(1).

PMID: 38203402 PMC: 10779126. DOI: 10.3390/ijms25010232.

Neutralizing tumor-related inflammation and reprogramming of cancer-associated fibroblasts by Curcumin in breast cancer therapy.

Jalilian E, Abolhasani-Zadeh F, Afgar A, Samoudi A, Zeinalynezhad H, Langroudi L Sci Rep. 2023; 13(1):20770.

PMID: 38008819 PMC: 10679154. DOI: 10.1038/s41598-023-48073-w.

What nature has to offer: Opportunities for immuno-oncology.

Kousar R, Lin C, Patrick B, He M, Wu D, Li X J Food Drug Anal. 2023; 31(2):212-231.

PMID: 37335163 PMC: 10281724. DOI: 10.38212/2224-6614.3459.

References

Wang Y, Souabni A, Flavell R, Wan Y . An intrinsic mechanism predisposes Foxp3-expressing regulatory T cells to Th2 conversion in vivo. J Immunol. 2010; 185(10):5983-92. PMC: 2974034. DOI: 10.4049/jimmunol.1001255. View

Whelan M, Casey G, Larkin J, Guinn B, OSullivan G, Tangney M . Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. PLoS One. 2014; 9(5):e97602. PMC: 4022586. DOI: 10.1371/journal.pone.0097602. View

Singh K, Gatzka M, Peters T, Borkner L, Hainzl A, Wang H . Reduced CD18 levels drive regulatory T cell conversion into Th17 cells in the CD18hypo PL/J mouse model of psoriasis. J Immunol. 2013; 190(6):2544-53. DOI: 10.4049/jimmunol.1202399. View

Tudyka V, Blomqvist L, Beets-Tan R, Boelens P, Valentini V, van de Velde C . EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review. Eur J Surg Oncol. 2014; 40(4):469-75. DOI: 10.1016/j.ejso.2013.10.029. View

Pei S, Wang J, Wang X, Zhang Q, Zhang H . Correlation of survivin, p53 and Ki-67 in laryngeal cancer Hep-2 cell proliferation and invasion. Asian Pac J Trop Med. 2015; 8(8):636-42. DOI: 10.1016/j.apjtm.2015.07.007. View

Xu H . Th1 cytokine-based immunotherapy for cancer. Hepatobiliary Pancreat Dis Int. 2014; 13(5):482-94. DOI: 10.1016/s1499-3872(14)60305-2. View

Galaine J, Borg C, Godet Y, Adotevi O . Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel). 2015; 3(3):490-502. PMC: 4586463. DOI: 10.3390/vaccines3030490. View

Lai C, August S, Behar R, Polak M, Ardern-Jones M, Theaker J . Characteristics of immunosuppressive regulatory T cells in cutaneous squamous cell carcinomas and role in metastasis. Lancet. 2015; 385 Suppl 1:S59. DOI: 10.1016/S0140-6736(15)60374-9. View

Vegran F, Apetoh L, Ghiringhelli F . Th9 cells: a novel CD4 T-cell subset in the immune war against cancer. Cancer Res. 2015; 75(3):475-9. DOI: 10.1158/0008-5472.CAN-14-2748. View

10.

Liu D, Thakor A, Baerlocher M, Alshammari M, Lim H, Kos S . A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. Future Oncol. 2015; 11(9):1421-8. DOI: 10.2217/fon.15.3. View

11.

Caserta S, Borger J, Zamoyska R . Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens. Crit Rev Immunol. 2012; 32(2):97-126. DOI: 10.1615/critrevimmunol.v32.i2.10. View

12.

Childs R, Carlsten M . Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov. 2015; 14(7):487-98. DOI: 10.1038/nrd4506. View

13.

Li Y, Niu Y, Sun Y, Zhang F, Liu C, Fan L . Role of phytochemicals in colorectal cancer prevention. World J Gastroenterol. 2015; 21(31):9262-72. PMC: 4541379. DOI: 10.3748/wjg.v21.i31.9262. View

14.

Kunnumakkara A, Anand P, Aggarwal B . Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008; 269(2):199-225. DOI: 10.1016/j.canlet.2008.03.009. View

15.

Zhao G, Lu Z, Tang L, Wu Z, Wang D, Zheng J . Curcumin inhibits suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. Int Immunopharmacol. 2012; 14(1):99-106. DOI: 10.1016/j.intimp.2012.06.016. View

16.

Lee 4th M, Xu S, Fitzpatrick E, Sharma A, Graves H, Czerniecki B . Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine. PLoS One. 2013; 8(11):e74698. PMC: 3823870. DOI: 10.1371/journal.pone.0074698. View

17.

Kiniwa Y, Li J, Wang M, Sun C, Lee J, Wang R . Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells. PLoS One. 2015; 10(5):e0124094. PMC: 4439028. DOI: 10.1371/journal.pone.0124094. View

18.

He Z, Shi C, Wen H, Li F, Wang B, Wang J . Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011; 29(3):208-13. DOI: 10.3109/07357907.2010.550592. View

19.

Janikashvili N, Bonnotte B, Katsanis E, Larmonier N . The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol. 2011; 2011:430394. PMC: 3216392. DOI: 10.1155/2011/430394. View

20.

Wang J, Du Y, Liu X, Cho W, Yang Y . MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer. Biomed Res Int. 2015; 2015:823620. PMC: 4438141. DOI: 10.1155/2015/823620. View